111 Inc. (YI) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
111 Inc. (YI) advanced +0.34% to $2.98, trading at 6% of its 52-week range ($2.48 – $11.17). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising three independent directors,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -9.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on YI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for YI. Explore sector supply chains on /butterfly.
Across 146 tracked Consumer Staples securities in the Roarable RQD universe, 111 Inc. (YI) ranks #116 by composite RQD confidence (42/100, grade D-) and #116 by equity capitalization ($26.2M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with YI at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| YI
ACTIVE
111 Inc. | D- | 42/100 | — | 5.8% | -20.5% | +0.34% | $26.2M | Benchmark Subject |
| PETS PetMed Express Inc. | E | 26/100 | — | 28.1% | -35.0% | -0.84% | $25.6M | /pets-vs-yi → |
| RDGT Ridgetech Inc. | D- | 43/100 | — | 3.6% | — | -2.45% | $3.0M | /rdgt-vs-yi → |
| GRDN Guardian Pharmacy Services Inc. (Class A) | B+ | 77/100 | 52.1x | 20.2% | 37.7% | +0.30% | $2.56B | /grdn-vs-yi → |
| CVS CVS Health Corporation | C- | 61/100 | 65.3x | 45.0% | 2.6% | +0.42% | $115.53B | /cvs-vs-yi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), 111 Inc. (YI) reported GAAP revenue of $1.80B (-9.0% vs. FY2024 revenue of $1.97B , and -14.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $17.0M, and free cash flow of $16.4M (-51.7% YoY). On the balance sheet, YI closed FY2025 with $314.6M in total assets against $0 in total debt (Altman Z-Score: 3.34, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.80B | $0 | $17.0M | $16.4M | $314.6M | — |
| FY2024 (FY) | 2024-12-31 | $1.97B | $0 | $36.0M | $34.0M | $381.9M | — |
| FY2023 (FY) | 2023-12-31 | $2.11B | $0 | -$63.0M | -$63.0M | — | — |
As of 2026-11-01, 111 Inc. (NASDAQ: YI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $2.98 (+0.34% 1D, market cap $26.2M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 146 tracked Consumer Staples issuers, YI ranks #116 in composite RQD confidence.
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), YI carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 5.8%, and ROIC of -20.5%. By comparison, PETS (PetMed Express Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.6M) and RDGT (Ridgetech Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
Per YI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001738906), 111 Inc. generated $1.80B in revenue (-9.0% YoY), $0 in net income, and $16.4M in free cash flow against $314.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
YI last traded at $2.98 (+0.34% on volume of 100,412 shares), positioning the stock -10.24% below its 50-day simple moving average ($3.32) and -41.11% below its 200-day simple moving average ($5.06). Across its 52-week range of $2.48 to $11.17, YI sits at the 5.8% percentile with a 14-day RSI of 32.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.4% ($2.70 to $3.26).
Why YI Stock advanced +0.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.